ArticleOncotarget2016

S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.

Rachel L Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.